Education
About Us
Working with TipRanks
Follow Us
Rein Therapeutics, Inc (RNTX)
:RNTX
RNTX Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RNTX Stock 12 Month Forecast
Average Price Target
$8.00
▲(525.00% Upside)
| Highest Price Target$10.00 | Average Price Target$8.00 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10
Buy
681.25%
Upside
Reiterated
11/18/25
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth PotentialValuation and Risks. Our $10 price target is based on a discounted cash flow (DCF) model that applies a 16.9% weighted average cost of capital (WACC), a 7.0x exit multiple to 2036 estimates, and a 2.3% terminal growth rate. Our peak sales projections for LTI-03 assume a 30% probability of success, reflecting the early stage of development, historical setbacks in idiopathic pulmonary fibrosis (IPF), and the company’s current limited cash runway, which will need to be extended to complete the ongoing Phase 2 trial.
Brookline Capital Markets
$6
Buy
368.75%
Upside
Upgraded
11/03/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10
Buy
681.25%
Upside
Reiterated
11/18/25
Rein Therapeutics: Buy Rating Driven by Innovative IPF Treatment and Strong Growth PotentialValuation and Risks. Our $10 price target is based on a discounted cash flow (DCF) model that applies a 16.9% weighted average cost of capital (WACC), a 7.0x exit multiple to 2036 estimates, and a 2.3% terminal growth rate. Our peak sales projections for LTI-03 assume a 30% probability of success, reflecting the early stage of development, historical setbacks in idiopathic pulmonary fibrosis (IPF), and the company’s current limited cash runway, which will need to be extended to complete the ongoing Phase 2 trial.
Brookline Capital Markets
$6
Buy
368.75%
Upside
Upgraded
11/03/25
Best Analysts Covering Rein Therapeutics
1 Month
xxx
Success Rate
3/4 ratings generated profit
Average Return
+13.40%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +13.40% per trade.
3 Months
xxx
Success Rate
4/4 ratings generated profit
Average Return
+22.93%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +22.93% per trade.
1 Year
Success Rate
4/4 ratings generated profit
Average Return
+37.92%
reiterated a sell rating 8 months ago
Copying Owen Dosehart's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +37.92% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
Average Return
+36.95%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +36.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
RNTX Analyst Recommendation Trends
Rating
Jan 25
Apr 25
Aug 25
Sep 25
Nov 25
Strong Buy
2
1
1
1
4
Buy
0
0
0
0
0
Hold
0
0
1
1
1
Sell
5
6
4
1
0
Strong Sell
0
0
0
0
0
total
7
7
6
3
5
Each month's total comprises the sum of three months' worth of ratings.
RNTX Financial Forecast
RNTX Stock Forecast FAQ
What is RNTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Rein Therapeutics, Inc’s 12-month average price target is 8.00.
What is RNTX’s upside potential, based on the analysts’ average price target?
Rein Therapeutics, Inc has 525.00% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RNTX a Buy, Sell or Hold?
Rein Therapeutics, Inc has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Rein Therapeutics, Inc’s price target?
The average price target for Rein Therapeutics, Inc is 8.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 525.00% Increase from the current price of $1.28.
The highest analyst price target is $10.00 ,the lowest forecast is $6.00. The average price target represents 525.00% Increase from the current price of $1.28.
What do analysts say about Rein Therapeutics, Inc?
Rein Therapeutics, Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of RNTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.